logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

April 2021

Tisagenlecleucel for relapsed or refractory follicular lymphoma

Tisagenlecleucel is in clinical development for the treatment of relapsed or refractory follicular lymphoma. Follicular lymphoma is the most common type of slow-growing lymphoma that develops in B-cells (a type of immune cell). Relapsed refers to a disease that grows again after a period of remission while refractory refers to a disease that does not …

Drugs

April 2021

Capmatinib for advanced non-small cell lung cancer

Capmatinib is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Symptoms of lung cancer include a persistent cough, shortness of breath, …

Drugs

March 2021

Crizotinib for paediatric ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour

Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumour (IMT) are both rare conditions that usually affect children and young adults. ALCL is a type of cancer that occurs when T-cells, which contribute to the body’s immune system, become abnormal. IMTs are most commonly non-cancerous (benign), however in some cases the tumour can become cancerous (malignant). Both conditions can be ALK-positive (ALK+), this means that the tumour cells have a mutation in anaplastic lymphoma kinase (ALK) resulting in uncontrolled cell replication. These conditions may not be able to be treated through surgical removal of the tumour (unresectable); they may also come back after treatment (relapse) or be resistant to current treatment options (refractory).

Drugs

March 2021

Pembrolizumab in combination with lenvatinib for advanced melanoma – first line

Pembrolizumab is an immunotherapy, meaning it stimulates the body’s immune system by triggering T-cells (a type of white blood cells) to find and kill cancer cells. Lenvatinib is a targeted therapy drug that inhibits cancer growth by preventing the formation of new blood vessels. These drugs modulate different aspects of tumour biology, combining them, may result in improved efficacy and help overcome resistance to immunotherapy. Pembrolizumab in combination with lenvatinib (pembrolizumab administered intravenously and lenvatinib administered orally) would offer an additional first-line treatment option for previously untreated and unresectable advanced melanoma.

Drugs

March 2021

Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line

Cemiplimab in combination with chemotherapy is in clinical development for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Symptoms of lung cancer include a persistent cough, shortness of breath, coughing up blood, aches and pains in the chest or shoulder, loss of appetite, weight loss and fatigue. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Advanced NSCLC is not usually curable; there is therefore the need for additional treatment options.

Drugs

February 2021

Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line

Oral cabozantinib is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of enzymes known as tyrosine kinases which can be found in certain receptors in cancer cells. Intravenous atezolizumab is a monoclonal antibody, a type of protein designed to recognise and attach to a protein called PD-L1, which is present on many cancer cells. Their combination has shown promising antitumour activity and tolerability in patients with solid tumours including HCC. If licensed, cabozantinib in combination with atezolizumab will provide an additional first-line treatment option for patients with advanced HCC.

Drugs

February 2021

Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line

Loncastuximab tesirine is administered by intravenous infusion. It is an antibody-drug conjugate (ADC) where an antibody is joined to a drug that is designed to kill lymphoma cells. The antibody targets a protein called CD19, which is found on the surface of lymphoma cells. The drug is then released into the lymphoma cells resulting in the death of these cells. If licenced, loncastuximab tesirine will offer an additional treatment option for patients with relapsed or refractory DLBCL.

Drugs

February 2021

Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line

Isatuximab is an anti-CD38 monoclonal antibody with a multi-modal action for killing tumor cells via direct tumor targeting and immune cell engagement. On review and approval, isatuximab in addition to standard combination chemotherapy treatment with bortezomib, lenalidomide and dexamethasone will offer an additional first-line treatment option for patients with newly diagnosed MM who are not eligible for ASCT.

Drugs

January 2021

Belzutifan for von Hippel-Lindau disease-associated clear cell renal cell carcinoma – first line

Belzutifan is in clinical development for the treatment of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). VHL is a hereditary disease that results in the body producing an increased amount of the protein hypoxia inducible factor (HIF) – 2α. This leads to an increased risk of tumours developing in various parts of the body including the kidney. Renal cell carcinoma (RCC) is the most common type of kidney cancer. ccRCC is named as such because when this type of tumour is viewed under a microscope the cells appear clear. Currently patients with VHL disease have limited treatment options which focus on surgically removing tumours once they have developed.

Drugs

January 2021

Pembrolizumab for recurrent or metastatic nasopharyngeal cancer

Pembrolizumab is an immunotherapy drug administered by intravenous (IV) infusion. It works by improving the activity of white blood cells (T-cells) by blocking a protein, PD-L1, thereby increasing the ability of the immune system to kill cancer cells. If licenced, pembrolizumab could provide an additional treatment option for patients with platinum pre-treated recurrent or metastatic nasopharyngeal cancer.

Get Alerts